Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc. is engaged in the development and commercialization of innovative therapies for the treatment of eye diseases.

Metric
Company Name	Aerie Pharmaceuticals, Inc.
Symbol	AERI
MSH ID	COM:AERIEPHARMA
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	US
Stage
Employee Count	376
Website	aeriepharma.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	194.13M
Revenue (LTM)
Revenue (NTM)
Gross Profit	167.29M
EBITDA	-7.81M
Operating Income	-45.31M
Net Income	-74.81M
EPS	-1.61
Diluted EPS	-1.61
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.86
Operating Profit Margin	-0.23
EBITDA Margin	-0.04
Net Profit Margin	-0.39
Return on Equity	-22.55
Return on Assets	-0.17
Return on Capital Employed	-0.15

COM:AERIEPHARMA

Aerie Pharmaceuticals, Inc.

Last Close

15.25

18/11 21:00

Volume Today

1.22M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.88
P/B Ratio	-4.45
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple	28.60

Metric
Days Sales Outstanding	271.64
Days Payables Outstanding	189.55
Days Inventory Outstanding	549.42
Operating Cycle	848.04
Cash Conversion Cycle	735.39
Asset Turnover	0.45

Metric
Operating Cash Flow	-99.15M
Free Cash Flow	-102.44M
Cash Flow to Debt	-0.38
Operating Cash Flow/Sales	-0.51
Free Cash Flow Yield

Metric
Cash & Equivalents	37.19M
Accounts Receivable	-12.81M
Inventory	40.41M
Goodwill
Debt to Capitalization	1.07
Debt to Assets	0.90
Current Ratio	2.27
Quick Ratio	2.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.12
R&D to Revenue	0.67
SG&A to Revenue